Nuvectis Pharma, Inc. - Common Stock — Bilancio Trimestrale (NASDAQ:NVCT) | MetaTrader

Apri il grafico completo Full chart

Notizie

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

Nuvectis avvia trial di fase 1b combinando NXP900 con osimertinib

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

Nuvectis Pharma: H.C. Wainwright conferma rating Buy con target di $10

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

Kaplan acquista azioni Nuvectis Pharma (NVCT) per un valore di $64.240

Il presidente di Nuvectis Pharma Bentsur acquista azioni per $28.600

Il direttore di Nuvectis Pharma Sanchez acquista azioni NVCT per 75.000$

H.C. Wainwright conferma il rating Buy su Nuvectis Pharma con target di $10

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors